Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Kamilla W Miskowiak; Maj Vinberg; Catherine J Harmer; Hannelore Ehrenreich; Lars V Kessing

doi:10.1007/s00213-011-2511-1

Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Kamilla W Miskowiak, Maj Vinberg, Catherine J Harmer, Hannelore Ehrenreich, Lars V Kessing

Research output: Contribution to journal › Journal article › Research › peer-review

66 Citations (Scopus)

Abstract

Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

Original language	English
Journal	Psychopharmacology
Volume	219
Issue number	3
Pages (from-to)	687-98
Number of pages	12
ISSN	0033-3158
DOIs	https://doi.org/10.1007/s00213-011-2511-1
Publication status	Published - 2012

Access to Document

10.1007/s00213-011-2511-1

Cite this

@article{db44bbf6be8646afb0331d5e0022a3ec,

title = "Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression",

abstract = "Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.",

author = "Miskowiak, {Kamilla W} and Maj Vinberg and Harmer, {Catherine J} and Hannelore Ehrenreich and Kessing, {Lars V}",

year = "2012",

doi = "10.1007/s00213-011-2511-1",

language = "English",

volume = "219",

pages = "687--98",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Erythropoietin

T2 - a candidate treatment for mood symptoms and memory dysfunction in depression

AU - Miskowiak, Kamilla W

AU - Vinberg, Maj

AU - Harmer, Catherine J

AU - Ehrenreich, Hannelore

AU - Kessing, Lars V

PY - 2012

Y1 - 2012

N2 - Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

AB - Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

U2 - 10.1007/s00213-011-2511-1

DO - 10.1007/s00213-011-2511-1

M3 - Journal article

C2 - 21947319

SN - 0033-3158

VL - 219

SP - 687

EP - 698

JO - Psychopharmacology

JF - Psychopharmacology

IS - 3

ER -